Palisade Bio (NASDAQ:PALI) stock is on the rise Friday after the biopharmaceutical company got an upgrade from an analyst.
Maxim Group is behind today’s upgrade for PALI stock. This saw its analysts upgrade the company’s shares from a “hold” rating to a “buy” rating. For the record, there’s not much analyst coverage of Palisade Bio’s shares. One other firm, Ladenburg Thalm, has a “buy” rating for the stock.
Maxim Group doesn’t include a price target for PALI stock in its latest coverage. When checking the other coverage of Palisade Bio, there’s a $5 price target for the shares from Ladenburg Thalm that was issued in February.
How Investors Are Reacting to the PALI Stock Upgrade
Investors appear hopeful on Friday following the upgrade news. This has the company’s shares seeing incredibly heavy trading today. As of this writing, more than 2 million shares of the stock have changed hands. To put that in perspective, the company’s daily average trading volume is closer to 1.2 million shares.
Palisade Bio is a biopharmaceutical company focused on the development of medications for specific diseases. Its major goal is the creation and commercialization of treatments for diseases affecting loss of gastrointestinal barrier integrity.
PALI stock is up 35.9% in pre-market trading on Friday.
Investors looking for more of the latest stock market news will want to keep reading!
InvestorPlace is home to all of the hottest stock market coverage traders need for Friday! That includes the biggest pre-market stock movers from this morning, as well as the latest concerning First Republic Bank (NYSE:FRC) stock and other companies. You can catch up on all of this news by reading the links below!
More Friday Stock Market News
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
- FRC Stock Price Predictions: Will First Republic Bank Shares Plunge to $3?
- MCB Stock Alert: Will Metropolitan Bank Be the Next to Fail?
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risk.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.